布索珠单抗

**布索珠单抗**
单克隆抗体
种类	完整抗体
目標	骨硬化蛋白
臨床資料
ATC碼	未分配;
识别信息
CAS号	1132758-87-2
ChemSpider	none;
UNII	83YOM0NEL5;
KEGG	D10094 ;
化学信息
化学式	C6462H9852N1684O2030S46
摩尔质量	145,086.42 g·mol−1

布索珠单抗（INN：Blosozumab）是一种人源化单克隆抗体。它与骨硬化蛋白结合（一种成骨细胞活性的负调节因子）。阻断硬骨素活性可以导致骨密度增加。^[1]布索珠单抗已针对男性和绝经后女性骨质疏松症的治疗进行了研究。布索珠单抗的临床试验表明该抗体具有良好的耐受性并能有效产生骨合成代谢作用。^[2]

布索珠单抗由礼来公司开发。

参考资料[编辑]

^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 (PDF). WHO Drug Information. 2011, 25 (2). ^{[失效連結]}
^ McColm J, Hu L, Womack T, Tang CC, Chiang AY. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. Journal of Bone and Mineral Research. April 2014, 29 (4): 935–43. PMID 23996473. doi:10.1002/jbmr.2092 .

[1] World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 (PDF). WHO Drug Information. 2011, 25 (2). ^{[失效連結]}

[2] McColm J, Hu L, Womack T, Tang CC, Chiang AY. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. Journal of Bone and Mineral Research. April 2014, 29 (4): 935–43. PMID 23996473. doi:10.1002/jbmr.2092 .

[1]

[2]